Pralatrexate in patients with relapsed and refractory T-cell lymphomas: real world data
Küçük Resim Yok
Tarih
2023
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Aim: T-cell lymphomas are a subtype of Non-Hodgkin lymphoma with a poor prognosis and treatment options are limited. Pralatrexate, an antimetabolite drug, has been approved for the treatment of relapsed and refractory T-cell lymphoma. Materials and Methods: Our study retrospectively evaluated relapsed and refractory T-cell lymphoma patients who received pralatrexate in terms of efficacy and safety of the drug. Results: A total of 13 patients were recruited. The median age at diagnosis was 63 years. The most common histologic types were mycosis fungoides with large cell transformation (31%) and angioimmunoblastic T-cell lymphoma (31%). The median number of prior systemic therapies before pralatrexate was 2 (range 1-6). The most common side effect was mucositis (54%). The overall response rate was 38% (15% complete remission and 23% partial remission). The median OS was 32±6.5 months and PFS was 6.78±1.6 months. Conclusion: Our study provided real-world data on the efficacy and safety of pralatrexate and supports current literature. This drug has acceptable toxicity and significant effectiveness on peripheral T-cell lymphomas.
Açıklama
Anahtar Kelimeler
Kaynak
Ege Tıp Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
62
Sayı
2
